This 2022 Recommendation Statement from the US Preventive Services Task Force recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years (B recommendation) and concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children 11 years or younger (I statement) and of screening for suicide risk in children and adolescents (I statement).
Source: JAMA Online First